Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + SBRT in symptomatic metastatic prostate cancer
NCT02998242Completed
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- May 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of Rivoceranib in prostate cancer (PCa) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Biochemical Disease Free Survival at 2 years. Started May 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02998242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998242.